FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:584-590 August 27, 1998 Number 9 Next

	Full Text PDF Editorial by Adamson, J. W. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background In patients with end-stage renal disease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially. We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis.

Methods We studied 1233 patients with clinical evidence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study. The median duration of treatment was 14 months. The primary end point was the length of time to death or a first nonfatal myocardial infarction.

Results After 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the low-hematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9). Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted. The causes of death in the two groups were similar. The mortality rates decreased with increasing hematocrit values in both groups. The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group.

Conclusions In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.

Source Information

From the Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit (A.B.); the Department of Internal Medicine, Division of Nephrology, University of Virginia Health Sciences Center, Charlottesville (W.K.B.); Amgen, Thousand Oaks, Calif. (J.K.B., J.C.E., D.M.O., D.A.G.); the Department of Medicine, Division of Nephrology, University of California at Los Angeles, Los Angeles (A.R.N.); and the Department of Medicine, Nephrology Division, Duke University Medical Center, Durham, N.C. (S.J.S.).

Address reprint requests to Dr. Goodkin at Clinical Research, Amgen, 1 Amgen Center Dr., Thousand Oaks, CA 91320.

Full Text of this Article

Related Letters:

Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Undergoing Hemodialysis and Receiving Epoetin
Sklar A. H., Narsipur S., González F., Nissenson A. R., Schwab S. J., Goodkin D. A.
Extract | Full Text  
N Engl J Med 1998; 339:2023-2024, Dec 31, 1998. Correspondence

This article has been cited by other articles:

• Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P., Anker, S. D., Knusel, B., Sun, Y., Wasserman, S. M., van Veldhuisen, D. J. (2009). The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. Eur J Heart Fail 11: 1071-1077 [Abstract] [Full Text]  
• Miskulin, D., Bragg-Gresham, J., Gillespie, B. W., Tentori, F., Pisoni, R. L., Tighiouart, H., Levey, A. S., Port, F. K. (2009). Key Comorbid Conditions that Are Predictive of Survival among Hemodialysis Patients. CJASN 4: 1818-1826 [Abstract] [Full Text]  
• Bacchus, S., O'Mara, N., Manley, H., Fishbane, S. (2009). Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists. The Annals of Pharmacotherapy 43: 1857-1866 [Abstract] [Full Text]  
• Treleaven, D. J, Clase, C. M (2009). Use of erythropoietins in patients with renal transplants. BMJ 339: b3825-b3825 [Full Text]  
• Heinze, G., Kainz, A., Horl, W. H, Oberbauer, R. (2009). Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study. BMJ 339: b4018-b4018 [Abstract] [Full Text]  
• Ibrahim, H. N., Ishani, A., Guo, H., Gilbertson, D. T. (2009). Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older. Nephrol Dial Transplant 24: 3138-3143 [Abstract] [Full Text]  
• Hadland, B. K., Longmore, G. D. (2009). Erythroid-Stimulating Agents in Cancer Therapy: Potential Dangers and Biologic Mechanisms. JCO 27: 4217-4226 [Abstract] [Full Text]  
• Besarab, A., Horl, W. H., Silverberg, D. (2009). Iron Metabolism, Iron Deficiency, Thrombocytosis, and the Cardiorenal Anemia Syndrome. The Oncologist 14: 22-33 [Abstract] [Full Text]  
• McMurray, J. J.V., Anand, I. S., Diaz, R., Maggioni, A. P., O'Connor, C., Pfeffer, M. A., Polu, K. R., Solomon, S. D., Sun, Y., Swedberg, K., Tendera, M., van Veldhuisen, D. J., Wasserman, S. M., Young, J. B., on behalf of the RED-HF Committees and Investigato, (2009). Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail 11: 795-801 [Abstract] [Full Text]  
• Singh, A. K., Himmelfarb, J., Szczech, L. A. (2009). Resolved: Targeting a Higher Hemoglobin Is Associated with Greater Risk in Patients with CKD Anemia: Pro. J. Am. Soc. Nephrol. 20: 1436-1443 [Abstract] [Full Text]  
• Moossavi, S., Freedman, B. I. (2009). Treating Anemia With Erythropoiesis-Stimulating Agents: Effects on Quality of Life. Arch Intern Med 169: 1100-1101 [Full Text]  
• Clement, F. M., Klarenbach, S., Tonelli, M., Johnson, J. A., Manns, B. J. (2009). The Impact of Selecting a High Hemoglobin Target Level on Health-Related Quality of Life for Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. Arch Intern Med 169: 1104-1112 [Abstract] [Full Text]  
• Hage, F. G., Venkataraman, R., Zoghbi, G. J., Perry, G. J., DeMattos, A. M., Iskandrian, A. E. (2009). The scope of coronary heart disease in patients with chronic kidney disease.. J Am Coll Cardiol 53: 2129-2140 [Abstract] [Full Text]  
• Chan, K., Moran, J., Hlatky, M., Lafayette, R. (2009). Protocol adherence and the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 24: 1956-1962 [Abstract] [Full Text]  
• Ensor, C. R, Kockler, D. R, Dugger, R. W, Hylton-Gravatt, L. A. (2009). Erythropoiesis-Stimulating Agents: Creation and Validation of a Computerized Prescriber Order Entry Alert. The Annals of Pharmacotherapy 43: 1143-1144 [Full Text]  
• Arneson, T. J., Zaun, D., Peng, Y., Solid, C. A., Dunning, S., Gilbertson, D. T. (2009). Comparison of methodologies to characterize haemoglobin variability in the US Medicare haemodialysis population. Nephrol Dial Transplant 24: 1378-1383 [Full Text]  
• Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90 [Full Text]  
• 2005 WRITING COMMITTEE MEMBERS, , Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., Oates, J. A., Rahko, P. S., Silver, M. A., Stevenson, L. W., Yancy, C. W. (2009). 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: Developed in Collaboration With the International Society for Heart and Lung Transplantation. Circulation 119: e391-e479 [Full Text]  
• Vaziri, N. D., Zhou, X. J. (2009). Potential mechanisms of adverse outcomes in trials of anemia correction with erythropoietin in chronic kidney disease. Nephrol Dial Transplant 24: 1082-1088 [Full Text]  
• Parfrey, P. S., Lauve, M., Latremouille-Viau, D., Lefebvre, P. (2009). Erythropoietin Therapy and Left Ventricular Mass Index in CKD and ESRD Patients: A Meta-Analysis. CJASN 4: 755-762 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2009). Erythropoietin Therapy, Hemoglobin Targets, and Quality of Life in Healthy Hemodialysis Patients: A Randomized Trial. CJASN 4: 726-733 [Abstract] [Full Text]  
• Krikorian, S. A. (2009). Managing Anemia of Chronic Kidney Disease. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 3: 135-146 [Abstract]  
• Ibrahim, H. N., Foley, R. N., Zhang, R., Gilbertson, D. T., Collins, A. J. (2009). Parenteral Iron Use: Possible Contribution to Exceeding Target Hemoglobin in Hemodialysis Patients. CJASN 4: 623-629 [Abstract] [Full Text]  
• Bradbury, B. D., Danese, M. D., Gleeson, M., Critchlow, C. W. (2009). Effect of Epoetin Alfa Dose Changes on Hemoglobin and Mortality in Hemodialysis Patients with Hemoglobin Levels Persistently below 11 g/dL. CJASN 4: 630-637 [Abstract] [Full Text]  
• Kalantar-Zadeh, K., Aronoff, G. R. (2009). Hemoglobin Variability in Anemia of Chronic Kidney Disease. J. Am. Soc. Nephrol. 20: 479-487 [Abstract] [Full Text]  
• Kazory, A., Ross, E. A. (2009). Anemia: the point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53: 639-647 [Abstract] [Full Text]  
• Spiegel, D. M., Evans, R. W., Gitlin, M., Mayne, T. J. (2009). Psychometric evaluation of the National Kidney Dialysis and Kidney Transplantation Study symptom checklist: reliability and validity. Nephrol Dial Transplant 24: 619-625 [Abstract] [Full Text]  
• Locatelli, F., Covic, A., Eckardt, K.-U., Wiecek, A., Vanholder, R., on behalf of the ERA-EDTA ERBP Advisory Board, (2009). Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24: 348-354 [Full Text]  
• Krapf, R., Hulter, H. N. (2009). Arterial Hypertension Induced by Erythropoietin and Erythropoiesis-Stimulating Agents (ESA). CJASN 4: 470-480 [Abstract] [Full Text]  
• Heung, M., Mueller, B. A, Segal, J. H (2009). Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease. The Annals of Pharmacotherapy 43: 276-282 [Abstract] [Full Text]  
• Trivedi, H., Xiang, Q., Klein, J. P. (2009). Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients. Nephrol Dial Transplant 24: 258-266 [Abstract] [Full Text]  
• Anker, S. D., Toto, R. (2009). Future perspectives on treatment with erythropoiesis-stimulating agents in high-risk patients. NDT Plus 2: i3-i8 [Abstract] [Full Text]  
• Foley, R. N., Curtis, B. M., Parfrey, P. S. (2008). Hemoglobin Targets and Blood Transfusions in Hemodialysis Patients without Symptomatic Cardiac Disease Receiving Erythropoietin Therapy. CJASN 3: 1669-1675 [Abstract] [Full Text]  
• von Drygalski, A., Biller, J. (2008). Anemia in Cystic Fibrosis: Incidence, Mechanisms, and Association With Pulmonary Function and Vitamin Deficiency. Nutr Clin Pract 23: 557-563 [Abstract] [Full Text]  
• Summers, S., Holdsworth, S., Sharples, E. (2008). The (re)challenging question of erythropoiesis-stimulating agents inducing pure red cell aplasia. Nephrol Dial Transplant 23: 3053-3055 [Full Text]  
• Chan, K. E., Lafayette, R. A., Whittemore, A. S., Hlatky, M. A., Moran, J. (2008). Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. Nephrol Dial Transplant 23: 2948-2956 [Abstract] [Full Text]  
• Singh, A. K., Kelley, K., Agarwal, R. (2008). Interpreting Results of Clinical Trials: A Conceptual Framework. CJASN 3: 1246-1252 [Full Text]  
• Kobayashi, H., Minatoguchi, S., Yasuda, S., Bao, N., Kawamura, I., Iwasa, M., Yamaki, T., Sumi, S., Misao, Y., Ushikoshi, H., Nishigaki, K., Takemura, G., Fujiwara, T., Tabata, Y., Fujiwara, H. (2008). Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 79: 611-620 [Abstract] [Full Text]  
• Anand, I. S. (2008). Anemia and Chronic Heart Failure: Implications and Treatment Options. J Am Coll Cardiol 52: 501-511 [Abstract] [Full Text]  
• Zarychanski, R. MD, Houston, D. S. MD PhD (2008). Anemia of chronic disease: A harmful disorder or an adaptive, beneficial response?. CMAJ 179: 333-337 [Full Text]  
• Swinkels, D. W., Wetzels, J. F. M. (2008). Hepcidin: a new tool in the management of anaemia in patients with chronic kidney disease?. Nephrol Dial Transplant 23: 2450-2453 [Full Text]  
• Sood, M. M., Pauly, R. P., Rigatto, C., Komenda, P. (2008). Left ventricular dysfunction in the haemodialysis population. NDT Plus 1: 199-205 [Abstract] [Full Text]  
• Copland, I. B., Jolicoeur, E. M., Gillis, M.-A., Cuerquis, J., Eliopoulos, N., Annabi, B., Calderone, A., Tanguay, J.-F., Ducharme, A., Galipeau, J. (2008). Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. Cardiovasc Res 79: 405-415 [Abstract] [Full Text]  
• Maekawa, K., Shoji, T., Emoto, M., Okuno, S., Yamakawa, T., Ishimura, E., Inaba, M., Nishizawa, Y. (2008). Influence of atherosclerosis on the relationship between anaemia and mortality risk in haemodialysis patients. Nephrol Dial Transplant 23: 2329-2336 [Abstract] [Full Text]  
• Walker, R. G. (2008). Erythropoietin Stimulating Agents and Epoetin Alfa Revisited: What's Really Relevant?. CJASN 3: 935-937 [Full Text]  
• Kilpatrick, R. D., Critchlow, C. W., Fishbane, S., Besarab, A., Stehman-Breen, C., Krishnan, M., Bradbury, B. D. (2008). Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis Patients. CJASN 3: 1077-1083 [Abstract] [Full Text]  
• Brookhart, M. A., Schneeweiss, S., Avorn, J., Bradbury, B. D., Rothman, K. J., Fischer, M., Mehta, J., Winkelmayer, W. C. (2008). The Effect of Altitude on Dosing and Response to Erythropoietin in ESRD. J. Am. Soc. Nephrol. 19: 1389-1395 [Abstract] [Full Text]  
• Tonelli, M. (2008). Randomized Trials in Hemodialysis Patients: Time to Step Up to the Plate. JAMA 299: 2205-2207 [Full Text]  
• DEMIRJIAN, S. G., NURKO, S. (2008). Anemia of chronic kidney disease: When normalcy becomes undesirable. Cleveland Clinic Journal of Medicine 75: 353-356 [Abstract] [Full Text]  
• Brunelli, S. M., Joffe, M. M., Israni, R. K., Yang, W., Fishbane, S., Berns, J. S., Feldman, H. I. (2008). History-Adjusted Marginal Structural Analysis of the Association between Hemoglobin Variability and Mortality among Chronic Hemodialysis Patients. CJASN 3: 777-782 [Abstract] [Full Text]  
• Watnick, S., Stooksbury, M., Winter, R., Riscoe, M., Cohen, D. M. (2008). White Thrombus Formation in Blood Tubing Lines in a Chronic Hemodialysis Unit. CJASN 3: 382-386 [Abstract] [Full Text]  
• Bennett, C. L., Silver, S. M., Djulbegovic, B., Samaras, A. T., Blau, C. A., Gleason, K. J., Barnato, S. E., Elverman, K. M., Courtney, D. M., McKoy, J. M., Edwards, B. J., Tigue, C. C., Raisch, D. W., Yarnold, P. R., Dorr, D. A., Kuzel, T. M., Tallman, M. S., Trifilio, S. M., West, D. P., Lai, S. Y., Henke, M. (2008). Venous Thromboembolism and Mortality Associated With Recombinant Erythropoietin and Darbepoetin Administration for the Treatment of Cancer-Associated Anemia. JAMA 299: 914-924 [Abstract] [Full Text]  
• Kazory, A., Ross, E. A. (2008). Contemporary Trends in the Pharmacological and Extracorporeal Management of Heart Failure: A Nephrologic Perspective. Circulation 117: 975-983 [Abstract] [Full Text]  
• Kapoian, T., O'Mara, N. B., Singh, A. K., Moran, J., Rizkala, A. R., Geronemus, R., Kopelman, R. C., Dahl, N. V., Coyne, D. W. (2008). Ferric Gluconate Reduces Epoetin Requirements in Hemodialysis Patients with Elevated Ferritin. J. Am. Soc. Nephrol. 19: 372-379 [Abstract] [Full Text]  
• Ghali, J. K., Anand, I. S., Abraham, W. T., Fonarow, G. C., Greenberg, B., Krum, H., Massie, B. M., Wasserman, S. M., Trotman, M.-L., Sun, Y., Knusel, B., Armstrong, P., on behalf of the Study of Anemia in Heart Failure, (2008). Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia. Circulation 117: 526-535 [Abstract] [Full Text]  
• Besarab, A., Goodkin, D. A., Nissenson, A. R. (2008). The Normal Hematocrit Study -- Follow-up. NEJM 358: 433-434 [Full Text]  
• Covic, A., Gusbeth-Tatomir, P., Goldsmith, D. (2008). Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. Nephrol Dial Transplant 23: 56-61 [Full Text]  
• Singh, A. K. (2008). Anemia of Chronic Kidney Disease. CJASN 3: 3-6 [Full Text]  
• Lipsic, E., Westenbrink, B. D., van der Meer, P., van der Harst, P., Voors, A. A., van Veldhuisen, D. J., Schoemaker, R. G., van Gilst, W. H. (2008). Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 10: 22-29 [Abstract] [Full Text]  
• Gilbertson, D. T., Ebben, J. P., Foley, R. N., Weinhandl, E. D., Bradbury, B. D., Collins, A. J. (2008). Hemoglobin Level Variability: Associations with Mortality. CJASN 3: 133-138 [Abstract] [Full Text]  
• Tonelli, M. (2007). Vitamin D in Patients with Chronic Kidney Disease: Nothing New under the Sun. ANN INTERN MED 147: 880-881 [Full Text]  
• Weiner, D. E., Miskulin, D. C., Seefeld, K., Ladik, V., Zager, P. G., Singh, A. K., Johnson, H. K., Meyer, K. B. (2007). Reducing versus Discontinuing Erythropoietin at High Hemoglobin Levels. J. Am. Soc. Nephrol. 18: 3184-3191 [Abstract] [Full Text]  
• Yang, W., Israni, R. K., Brunelli, S. M., Joffe, M. M., Fishbane, S., Feldman, H. I. (2007). Hemoglobin Variability and Mortality in ESRD. J. Am. Soc. Nephrol. 18: 3164-3170 [Abstract] [Full Text]  
• DeLoughery, T. G. (2007). Update in Hematology. ANN INTERN MED 147: 717-724 [Full Text]  
• Portoles, J., Lopez-Gomez, J. M., Gruss, E., Aljama, P., for the MAR Study Group, (2007). Course of Vascular Access and Relationship with Treatment of Anemia. CJASN 2: 1163-1169 [Abstract] [Full Text]  
• Fishbane, S., Besarab, A. (2007). Mechanism of Increased Mortality Risk with Erythropoietin Treatment to Higher Hemoglobin Targets. CJASN 2: 1274-1282 [Abstract] [Full Text]  
• Tefferi, A. (2007). Pharmaceutical Erythropoietin Use in Patients With Cancer: Is It Time to Abandon Ship or Just Drop Anchor?. Mayo Clin Proc. 82: 1316-1318 [Full Text]  
• Wish, J. B., Coyne, D. W. (2007). Use of Erythropoiesis-Stimulating Agents in Patients With Anemia of Chronic Kidney Disease: Overcoming the Pharmacological and Pharmacoeconomic Limitations of Existing Therapies. Mayo Clin Proc. 82: 1371-1380 [Abstract] [Full Text]  
• Macdougall, I. C., Eckardt, K.-U., Locatelli, F. (2007). Latest US KDOQI Anaemia Guidelines update what are the implications for Europe?. Nephrol Dial Transplant 22: 2738-2742 [Full Text]  
• Tanaka, Y., Joki, N., Hase, H. (2007). History of acute coronary events during the predialysis phase of chronic kidney disease is a strong risk factor for major adverse cardiac events in patients initiating haemodialysis. Nephrol Dial Transplant 22: 2917-2923 [Abstract] [Full Text]  
• Foley, R. N., Collins, A. J. (2007). End-Stage Renal Disease in the United States: An Update from the United States Renal Data System. J. Am. Soc. Nephrol. 18: 2644-2648 [Abstract] [Full Text]  
• Culleton, B. F., Walsh, M., Klarenbach, S. W., Mortis, G., Scott-Douglas, N., Quinn, R. R., Tonelli, M., Donnelly, S., Friedrich, M. G., Kumar, A., Mahallati, H., Hemmelgarn, B. R., Manns, B. J. (2007). Effect of Frequent Nocturnal Hemodialysis vs Conventional Hemodialysis on Left Ventricular Mass and Quality of Life: A Randomized Controlled Trial. JAMA 298: 1291-1299 [Abstract] [Full Text]  
• Chertow, G. M., Pupim, L. B., Block, G. A., Correa-Rotter, R., Drueke, T. B., Floege, J., Goodman, W. G., London, G. M., Mahaffey, K. W., Moe, S. M., Wheeler, D. C., Albizem, M., Olson, K., Klassen, P., Parfrey, P. (2007). Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): Rationale and Design Overview. CJASN 2: 898-905 [Abstract] [Full Text]  
• Schwenger, V., Morath, C., Zeier, M. (2007). Use of Erythropoietin after solid organ transplantation. Nephrol Dial Transplant 22: viii47-viii49 [Abstract] [Full Text]  
• Coyne, D. W. (2007). Epoetin Dosing and Dialysis Facility Ownership Reply. JAMA 298: 862-863 [Full Text]  
• Westenbrink, B. D., Lipsic, E., van der Meer, P., van der Harst, P., Oeseburg, H., Du Marchie Sarvaas, G. J., Koster, J., Voors, A. A., van Veldhuisen, D. J., van Gilst, W. H., Schoemaker, R. G. (2007). Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28: 2018-2027 [Abstract] [Full Text]  
• Ishani, A., Guo, H., Gilbertson, D. T., Liu, J., Dunning, S., Collins, A. J., Foley, R. N. (2007). Time to target haemoglobin concentration (11 g/dl) risk of hospitalization and mortality among incident dialysis patients. Nephrol Dial Transplant 22: 2247-2255 [Abstract] [Full Text]  
• Richardson, D., Hodsman, A., van Schalkwyk, D., Tomson, C., Warwick, G. (2007). Management of anaemia in haemodialysis and peritoneal dialysis patients (Chapter 8). Nephrol Dial Transplant 22: vii78-vii104 [Abstract] [Full Text]  
• Brimble, K. S., Clase, C. M. (2007). Hemoglobin Variability in Dialysis Patients. J. Am. Soc. Nephrol. 18: 2218-2220 [Full Text]  
• Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., Reddan, D. (2007). Anaemia of CKD--the CHOIR study revisited. Nephrol Dial Transplant 22: 1806-1810 [Full Text]  
• Lenga, I., Lok, C., Marticorena, R., Hunter, J., Dacouris, N., Goldstein, M. (2007). Role of Oral Iron in the Management of Long-Term Hemodialysis Patients. CJASN 2: 688-693 [Abstract] [Full Text]  
• Gilmartin, C. (2007). Pharmacist's role in managing anemia in patients with chronic kidney disease: Potential clinical and economic benefits. Am J Health Syst Pharm 64: S15-S22 [Abstract] [Full Text]